

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumention Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1477)

VOLUNTARY ANNOUNCEMENT
OT-502 APPROVED FOR REAL WORLD STUDY IN HAINAN BOAO

This announcement is made by Ocumention Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the “**Board**”) of directors of the Company is pleased to announce that the Group’s product, OT-502 (DEXYCU®) (9% dexamethasone implant), has been approved for carrying out real world study in Boao Lecheng International Medical Tourism Pilot Zone (博鳌樂城國際醫療旅遊先行區) in Hainan Province, the People’s Republic of China (the “**PRC**”), which may potentially accelerate the new drug application submission of OT-502 in the PRC. In July 2021, the phase III clinical trial of OT-502 was accepted by the Center for Drug Evaluation of the National Medical Products Administration of the PRC. Meanwhile, OT-502 was approved for pilot sales in Boao Lecheng International Medical Tourism Pilot Zone.

OT-502 is a single-dose, sustained-release solution of dexamethasone, a corticosteroid, for the treatment of postoperative inflammation. As of the date of this announcement, DEXYCU® is the first and only single-dose, sustained-release intracameral steroid for the treatment of postoperative inflammation that was approved by the United States Food and Drug Administration. The Group is developing OT-502 as a potential first-in-class treatment for postoperative inflammation associated with cataract surgery in China.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately commercialize OT-502 successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumention Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, August 17, 2021

As at the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE and Mr. Yiran HUANG as independent non-executive directors.